Researchers have found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.
Posts Tagged ‘Prostate Cancer’
An international randomized study finds intermittent androgen-deprivation therapy has some quality-of-life benefits, but overall survival times don’t measure up to those seen with continuous therapy.
A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The Phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.
Recent recommendations from the US Preventive Services Task Force advising elimination of routine prostate-specific antigen screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a new survey.
Scientists have discovered that a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments. To test more than a dozen different compounds, researchers pioneered a fully automated robotic system to identify several drugs, including thioridazine.
Following a period for public comment, the United States Preventive Services Task Force (USPSTF) released its final recommendation for prostate cancer screening. The Task Force now recommends against PSA-based screening for all men, regardless of age.
Statins drugs prescribed to treat high cholesterol may also work to slow prostate growth in men who have elevated PSA levels, according to a new analysis.
A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers.
Researchers have demonstrated that a hormone-depleting drug approved for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a new clinical study.
Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.